Skip to content

A Noninvasive Arterial Input Estimation Method for O-15 PET and Integrated PET/MR Scanning

A Noninvasive Arterial Input Estimation Method for O-15 PET and Integrated PET/MR Scanning

Status
Withdrawn
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03806751
Acronym
O-15 Water
Enrollment
0
Registered
2019-01-16
Start date
2025-02-01
Completion date
2027-02-01
Last updated
2024-03-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Validation of a New Noninvasive Method to Obtain the Arterial Input Function (AIF) Directly by PET Imaging

Brief summary

The overall aim of this project is to implement a non-invasive method of measuring quantitative regional cerebral blood flow (rCBF) on the UAB hybrid PET/MRI scanner to allow conducting such \[O-15\]water based scans with relative ease and safety in a large variety of important clinical and research applications. Participants will undergo imaging at baseline and after administration of a drug to increase cerebral blood flow to evaluate perfusion estimates during low and high flow states. The goal of this study is to generate data that will justify eliminating invasive arterial sampling in most \[O-15\]water-based PET protocols.

Interventions

DRUG[O-15]Water

All study participants with undergo brain imaging with \[O-15\]water-PET/MRI without and with administration of the carbonic anhydrase inhibitor acetazolamide. The PET tracer will be used to measure regional cerebral perfusion, and the administration of acetazolamide will lead to increased cerebral perfusion compared to baseline cerebral perfusion.

DRUGAcetazolamide

The administration of acetazolamide will lead to increased cerebral perfusion compared to baseline cerebral perfusion.

Sponsors

University of Alabama at Birmingham
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Intervention model description

Healthy volunteers

Eligibility

Sex/Gender
ALL
Age
19 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

* Six participants aged 19-60 years of age, male and female, with no evidence of neurological disease, will be recruited from UAB and the surrounding community.

Exclusion criteria

* Participants will be excluded if there is any evidence or history of claustrophobia or the subject has metallic implants or devices that are normally exclusion factors for MRI.

Design outcomes

Primary

MeasureTime frameDescription
Comparison of arterial sampling to non-invasive methods to measure regional cerebral blood flow using [O-15]water-PET/MRI3 yearsMeasurements of regional cerebral blood flow with \[O-15\]water-PET/MRI using arterial sampling versus non-invasive image-based input function estimates will be compared.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026